Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762)

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762)

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Measles mumps and rubella virus vaccine-(Priorix) (Primary) ; DTaP poliovirus vaccine; Measles mumps and rubella virus vaccine; Varicella zoster virus vaccine live
  • Indications Diphtheria; Herpes zoster; Measles; Mumps; Pertussis; Poliomyelitis; Rubella; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 May 2015 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015, according to to ClinicalTrials.gov record.
    • 11 May 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jul 2015, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top